1. Dursun D, Kim MC, Solomon A, Pflugfelder SC. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids.
Am J Ophthalmol 2001;132:8-13.
2. Hope-Ross MW, Chell PB, Kervick GN, et al. Oral tetracycline in the treatment of recurrent corneal erosions.
Eye (Lond) 1994;8(Pt 4):384-388.
3. Buxton JN, Fox ML. Superficial epithelial keratectomy in the treatment of epithelial basement membrane dystrophy: a preliminary report.
Arch Ophthalmol 1983;101:392-395.
4. Soong HK, Farjo Q, Meyer RF, Sugar A. Diamond burr superficial keratectomy for recurrent corneal erosions.
Br J Ophthalmol 2002;86:296-298.
5. McLean EN, MacRae SM, Rich LF. Recurrent erosion: treatment by anterior stromal puncture.
Ophthalmology 1986;93:784-788.
6. Kim SY, Ko BY. Evaluation of anterior stromal puncture using Nd:YAG laser for refractory recurrent corneal erosion.
J Korean Ophthalmol Soc 2015;56:331-338.
7. Choi M, Jung JW, Seo KY, et al. Comparison of Nd:YAG laser versus conservative management in the treatment of recurrent corneal erosion.
J Korean Ophthalmol Soc 2015;56:687-693.
8. Forster W, Grewe S, Atzler U, et al. Phototherapeutic keratectomy in corneal diseases.
Refract Corneal Surg 1993;9(2 Suppl):S85-S90.
9. Nishida T, Nakamura M, Ofuji K, et al. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea.
J Cell Physiol 1996;169:159-166.
10. van Setten GB, Viinikka L, Tervo T, et al. Epidermal growth factor is a constant component of normal human tear fluid.
Graefes Arch Clin Exp Ophthalmol 1989;227:184-187.
11. Gupta A, Monroy D, Ji Z, et al. Transforming growth factor beta-1 and beta-2 in human tear fluid.
Curr Eye Res 1996;15:605-614.
12. Liu L, Hartwig D, Harloff S, et al. An optimised protocol for the production of autologous serum eyedrops.
Graefes Arch Clin Exp Ophthalmol 2005;243:706-714.
13. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome.
Br J Ophthalmol 1999;83:390-395.
14. Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease.
Bone Marrow Transplant 2003;31:579-583.
15. Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease.
Br J Ophthalmol 2004;88:647-652.
16. Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study.
Am J Ophthalmol 2005;139:242-246.
17. Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients.
Cornea 2001;20:802-806.
18. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application.
Ophthalmology 1999;106:1984-1989.
19. Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies.
Br J Ophthalmol 2001;85:1188-1197.
20. Young AL, Cheng AC, Ng HK, et al. The use of autologous serum tears in persistent corneal epithelial defects.
Eye (Lond) 2004;18:609-614.
21. Jeng BH, Dupps WJ Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects.
Cornea 2009;28:1104-1108.
22. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy.
Ophthalmology 2004;111:1115-1120.
23. del Castillo JM, de la Casa JM, Sardina RC, et al. Treatment of recurrent corneal erosions using autologous serum.
Cornea 2002;21:781-783.
24. Knighton DR, Ciresi K, Fiegel VD, et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula.
Surg Gynecol Obstet 1990;170:56-60.
25. Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing: single and synergistic effects on partial thickness porcine skin wounds.
J Clin Invest 1989;84:640-646.
26. Alio JL, Abad M, Artola A, et al. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers.
Ophthalmology 2007;114:1286-1293.e1.
27. Alio JL, Pastor S, Ruiz-Colecha J, et al. Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma.
J Refract Surg 2007;23:617-619.
28. Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis.
Jpn J Ophthalmol 2012;56:544-550.
29. Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: growth factor enhancement for bone grafts.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638-646.
30. Peng Y, Huang S, Wu Y, et al. Platelet rich plasma clot releasate preconditioning induced PI3K/AKT/NFκB signaling enhances survival and regenerative function of rat bone marrow mesenchymal stem cells in hostile microenvironments.
Stem Cells Dev 2013;22:3236-3251.
31. Holzer MP, Auffarth GU, Specht H, Kruse FE. Combination of transepithelial phototherapeutic keratectomy and autologous serum eyedrops for treatment of recurrent corneal erosions.
J Cataract Refract Surg 2005;31:1603-1606.
32. Hartwig D, Harloff S, Liu L, et al. Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells: a potential agent for the treatment of ocular surface defects?
Transfusion 2004;44:1724-1731.
33. Sakimoto T, Shoji J, Yamada A, Sawa M. Upregulation of matrix metalloproteinase in tear fluid of patients with recurrent corneal erosion.
Jpn J Ophthalmol 2007;51:343-346.
34. Nurden AT. Platelets, inflammation and tissue regeneration.
Thromb Haemost 2011;105(Suppl 1):S13-S33.